Vasopressin
Vasopressin is a peptide, indexed here under Endocrine and immune signalling peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Endocrine and immune signalling peptides |
| CAS registry number | 113-79-1[1] |
| PubChem CID | 644077[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C46H65N15O12S2[1] |
| Molecular weight | 1084.2 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Vasopressin, also called arginine vasopressin or antidiuretic hormone, is a nonapeptide of the posterior pituitary. The Drugs@FDA register returned approved applications under this generic name; those products are recorded in the regulatory status field and are not what this page describes. A 1995 Proceedings of the National Academy of Sciences paper reports that it increases water permeability of the kidney collecting duct by inducing translocation of aquaporin-CD water channels, a 1984 Journal of Neuroscience paper reports tonic vasomotor control by the rostral ventrolateral medulla, and a 2006 Clinical Chemistry paper reports an assay for copeptin, a stable peptide derived from its precursor.
Clinical records include a 2008 New England Journal of Medicine trial of vasopressin versus norepinephrine infusion in septic shock and a 2006 paper in the same journal on tolvaptan, a selective oral V2-receptor antagonist. The remaining records are social neuroscience shared with oxytocin: a 1993 Nature paper on central vasopressin in pair bonding in prairie voles, a 2004 Frontiers in Neuroendocrinology review of release within the brain, 2008 Science and 2011 Nature Reviews Neuroscience articles on the two peptides in sociality and the human brain, a 2010 Neuron review on translation in social neuroscience, and a 2012 Trends in Neurosciences review on the balance of brain oxytocin and vasopressin.
[3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]Reported mechanism
A posterior pituitary nonapeptide acting at vasopressin receptors; the retrieved records report V2-receptor mediated aquaporin translocation in the kidney and central roles in social behaviour.
[3, 8]Stated in the titles of the cited 1995 Proceedings of the National Academy of Sciences and 1993 Nature papers.
Targets named in the cited records: vasopressin V1 and V2 receptors, aquaporin-2 translocation.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 10 application record(s) for this compound name (including ANDA211857, ANDA216963, ANDA212944, NDA212593, NDA217569, marketed as VASOPRESSIN, VASOPRESSIN IN DEXTROSE 5%, VASOPRESSIN IN SODIUM CHLORIDE 0.9%). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Vasopressin appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- arginine vasopressin
- AVP
- antidiuretic hormone
- ADH
Where this page sits
Research records
Cited research records for Vasopressin, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include Vasopressin
Compounds indexed next to it
- Oxytocin — Endocrine and immune signalling peptides
- Desmopressin — Endocrine and immune signalling peptides
Class page: Endocrine and immune signalling peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Vasopressin?
Vasopressin, also called arginine vasopressin or antidiuretic hormone, is a nonapeptide of the posterior pituitary. The Drugs@FDA register returned approved applications under this generic name; those products are recorded in the regulatory status field and are not what this page describes.
Which class is Vasopressin indexed under?
Vasopressin is indexed under Endocrine and immune signalling peptides. This class groups peptides whose retrieved literature concerns endocrine or immune signalling outside the growth hormone axis.
What does the FDA application register show for Vasopressin?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 10 application record(s) for this compound name (including ANDA211857, ANDA216963, ANDA212944, NDA212593, NDA217569, marketed as VASOPRESSIN, VASOPRESSIN IN DEXTROSE 5%, VASOPRESSIN IN SODIUM CHLORIDE 0.9%). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.
Sources
- PubChem Compound Summary for CID 644077, Argipressin. PubChem, National Library of Medicine (2026). pubchem:644077
- Drugs@FDA application register query for this compound, 10 application(s) returned: ANDA211857, ANDA216963, ANDA212944, NDA212593, NDA217569. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:vasopressin
- Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proceedings of the National Academy of Sciences of the United States of America (1995). pmid:7532304
- Tonic vasomotor control by the rostral ventrolateral medulla: effect of electrical or chemical stimulation of the area containing C1 adrenaline neurons on arterial pressure, heart rate, and plasma catecholamines and vasopressin. The Journal of neuroscience : the official journal of the Society for Neuroscience (1984). pmid:6699683
- Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clinical chemistry (2006). pmid:16269513
- Vasopressin versus norepinephrine infusion in patients with septic shock. The New England journal of medicine (2008). pmid:18305265
- Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. The New England journal of medicine (2006). pmid:17105757
- A role for central vasopressin in pair bonding in monogamous prairie voles. Nature (1993). pmid:8413608
- Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Frontiers in neuroendocrinology (2004). pmid:15589267
- Oxytocin, vasopressin, and the neurogenetics of sociality. Science (New York, N.Y.) (2008). pmid:18988842
- Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nature reviews. Neuroscience (2011). pmid:21852800
- The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron (2010). pmid:20346754
- Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends in neurosciences (2012). pmid:22974560
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.